Should you buy Intuitive Surgical (ISRG)?
Updated
Intuitive Surgical is a high-quality franchise — a perfect Piotroski financial-health score, 28% operating margins ranked best-in-class among peers, and four consecutive earnings beats — but the stock carries a forward multiple of 35x in a confirmed price downtrend with a put/call ratio of 5.85, arguing that the setup rewards waiting for either a better entry price or a technical reversal signal before adding exposure.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
The business scores a perfect 9 out of 9 on the Piotroski financial health scale, carries operating margins of 28%, ranks best-in-class on margins versus peers, and clears the Rule of 40 at a combined score of 44 — collectively reflecting a franchise with durable earnings quality and structural competitive strength. Quality breakdown | Operating margin stays above 25% and Piotroski F-Score remains at 8 or above for four consecutive quarters. | →Stable |
| CounterHigh margins in a medical device business can attract competitive responses or face pricing pressure from hospital procurement consolidation; a sole- and single-sourced supplier concentration flagged in company disclosures could also create a production disruption that temporarily compresses margins within a single quarter. | ||
Revenue is growing at 23% year-over-year and the combined growth-plus-margin score of 44 clears the Rule of 40 threshold, indicating the business is expanding without sacrificing profitability — a combination that typically supports a durable premium multiple. Growth breakdown | Revenue growth rate stays above 18% year-over-year for two consecutive quarters while gross margin remains above 60%. | →Stable |
| CounterThe sole- and single-sourced supplier risk flagged in company disclosures means any supply disruption could create a production shortfall that cuts into the revenue growth rate within a single quarter, and a 23% growth rate from this starting base will naturally decelerate as the installed base matures. | ||
The company has delivered four consecutive earnings beats with an average surprise of roughly 16%, demonstrating a consistent pattern of under-promising and over-delivering relative to analyst consensus. Catalyst breakdown | The beat streak extends to at least five consecutive quarters with each surprise staying above 5%. | →Stable |
| CounterA 16% average beat, while meaningful, is not dramatically above what well-covered large-caps routinely deliver; if Wall Street ratchets estimates upward in response to repeated outperformance, the manageable bar that produced these beats may rise to a level that is materially harder to clear. | ||
The business scores a perfect 9 out of 9 on the Piotroski financial health scale, carries operating margins of 28%, ranks best-in-class on margins versus peers, and clears the Rule of 40 at a combined score of 44 — collectively reflecting a franchise with durable earnings quality and structural competitive strength.
→Stable- Expectation
- Operating margin stays above 25% and Piotroski F-Score remains at 8 or above for four consecutive quarters.
CounterHigh margins in a medical device business can attract competitive responses or face pricing pressure from hospital procurement consolidation; a sole- and single-sourced supplier concentration flagged in company disclosures could also create a production disruption that temporarily compresses margins within a single quarter.
Revenue is growing at 23% year-over-year and the combined growth-plus-margin score of 44 clears the Rule of 40 threshold, indicating the business is expanding without sacrificing profitability — a combination that typically supports a durable premium multiple.
→Stable- Expectation
- Revenue growth rate stays above 18% year-over-year for two consecutive quarters while gross margin remains above 60%.
CounterThe sole- and single-sourced supplier risk flagged in company disclosures means any supply disruption could create a production shortfall that cuts into the revenue growth rate within a single quarter, and a 23% growth rate from this starting base will naturally decelerate as the installed base matures.
The company has delivered four consecutive earnings beats with an average surprise of roughly 16%, demonstrating a consistent pattern of under-promising and over-delivering relative to analyst consensus.
→Stable- Expectation
- The beat streak extends to at least five consecutive quarters with each surprise staying above 5%.
CounterA 16% average beat, while meaningful, is not dramatically above what well-covered large-caps routinely deliver; if Wall Street ratchets estimates upward in response to repeated outperformance, the manageable bar that produced these beats may rise to a level that is materially harder to clear.
▸ Show 2 more pillars▾ Show fewer
At a forward price-to-earnings multiple of 35x and a PEG ratio of 2.18, the stock already prices in substantial optimism; simultaneously, the price is in a confirmed downtrend below a declining 200-day moving average, creating a combination where the rich starting multiple leaves little room for earnings disappointment.
→Stable- Expectation
- Forward P/E compresses below 28x while the stock recovers above its 200-day moving average.
CounterA franchise with near-perfect financial health scores and a consistent beat record can sustain a premium multiple for extended periods; a rich valuation alone is not a sufficient catalyst for sustained drawdown if earnings continue to outperform consensus.
The options market shows a put/call ratio of 5.85 — an unusually high reading indicating that protective put purchasing far exceeds call activity, suggesting participants are collectively positioned for near-term downside risk.
→Stable- Expectation
- Put/call ratio normalizes below 2.0 in the 30 days following the next earnings release.
CounterAn elevated put/call ratio in a widely-held large-cap may reflect institutional holders adding hedges to existing long positions rather than outright directional short bets; if that is the case, the signal overstates bearish conviction and the ratio will normalize naturally as the hedges expire.
→ Full pillar scorecard with all 5 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The business scores a perfect 9 out of 9 on the Piotroski financial health scale, carries operating margins of 28%, ranks best-in-class on margins versus peers, and clears the Rule of 40 at a combined score of 44 — collectively reflecting a franchise with durable earnings quality and structural competitive strength.
Trip ifOperating margin compresses below 20% for 2 consecutive quarters.
- P2The company has delivered four consecutive earnings beats with an average surprise of roughly 16%, demonstrating a consistent pattern of under-promising and over-delivering relative to analyst consensus.
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P3Revenue is growing at 23% year-over-year and the combined growth-plus-margin score of 44 clears the Rule of 40 threshold, indicating the business is expanding without sacrificing profitability — a combination that typically supports a durable premium multiple.
Trip ifRevenue growth falls below 15% YoY for 2 consecutive quarters.
- P4At a forward price-to-earnings multiple of 35x and a PEG ratio of 2.18, the stock already prices in substantial optimism; simultaneously, the price is in a confirmed downtrend below a declining 200-day moving average, creating a combination where the rich starting multiple leaves little room for earnings disappointment.
Trip ifPrice crosses above the 200-day moving average and holds above it for at least 10 consecutive trading sessions while forward P/E compresses to below 28x.
- P5The options market shows a put/call ratio of 5.85 — an unusually high reading indicating that protective put purchasing far exceeds call activity, suggesting participants are collectively positioned for near-term downside risk.
Trip ifPut/call ratio falls below 2.0 for at least 3 consecutive options-expiration cycles.
How the engine reached this verdict
TrendMatrix's engine output for Intuitive Surgical, Inc. (ISRG) is HOLD_IF_HOLDING with medium conviction, score 6.0/10 at $403.33. None of the engine's positive-conviction paths (C-quality, D-momentum) cleared their gates — the F-path HOLD reflects balanced signals rather than directional conviction.
HOLD flips toward BUY_WAIT if momentum at 2.8 vs threshold 4.5 clears AND a co-confirming gate triggers. HOLD flips toward SELL if any of the currently-passing gates drop below threshold OR three or more dimensions fall below 4 simultaneously.
The engine is not issuing fresh-money entry targets at the current verdict. The technical entry zone is around — with a technical stop near $384.78 for existing positions. Asymmetric R:R is 5.24, below the threshold (≥2.0) at which the engine would actively flag fresh capital. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bull side: Strong earnings beat streak (4/4); High-quality business; Strong growth profile. On the bear side: Concentration risk — Supplier: sole- and single-sourced suppliers; Expensive valuation; Negative momentum. Active engine warnings: V9 Gate Failed: MOMENTUM:2.8<4.5, V9 Gate Failed: DEATH_CROSS:HARD_BLOCK.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates ISRG — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (4/4)
- ▸High-quality business
- ▸Strong growth profile
Bear case
- ▸Concentration risk — Supplier: sole- and single-sourced suppliers
- ▸Expensive valuation
- ▸Negative momentum